NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Enterin

Enterin

Private
Philadelphia, PennsylvaniaHealthcare & Life Scienceshttps://enterininc.com/

Last Round

Series A

Jul 17, 2017

Total Funding Raised

$12.7M

Company Overview

Enterin is a biotechnology company that develops novel drugs designed to offer treatments that target the gut-brain axis and modify the course of neurodegenerative disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

gut-brain axisneurodegenerative diseaseParkinson's diseasealpha-synuclein targetingenteric nervous systemsmall molecule drugsecond braindrug developmentclinical stage biopharmaENSmetabolic diseaseAlzheimer's diseaseautism

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Enterin Comps

Public and private peers based on sector, stage, and business model.

Enterin comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Enterin Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJul 17, 2017
View all Funding Rounds

Key People

Founding team and executive leadership

michael Zasloff

CEO

Executive Team

Michael Zasloff

Founder, Chairman And CEO

Founding Team

Richard Larson

Chief Executive Officer And Chief Medical Officer

Executive Team

Enterin Investors

Notable investors and investment history

Enterin investors
InvestorRounds
Scientia VenturesSeries A, VC Round
The Naissos GroupSeries A, VC Round
Indie Asset PartnersVC Round
View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 10, 2024

    Monthly visitors grew 1000% MoM, from 70 to 770.

  • Jul 17, 2017

    $13M round led by New Ventures III.

View all signals

Enterin Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Enterin Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Enterin's valuation, stock price, and market status.

Firmographic Details

HeadquartersPhiladelphia, Pennsylvania
Employee Range14
Year Founded2016
Last FundingJul 17, 2017

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.